Bioxyne Ltd
BXN
Company Profile
Business description
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
Contact
50 Clarence Street
Suite 506, Level 5
SydneyNSW2000
AUST: +61 290787669
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
30 June 2026
Employees
16
Stocks News & Analysis
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.80 | 23.20 | 0.26% |
| CAC 40 | 8,185.59 | 2.25 | 0.03% |
| DAX 40 | 25,122.98 | 18.28 | 0.07% |
| Dow JONES (US) | 51,032.46 | 363.49 | 0.72% |
| FTSE 100 | 10,374.58 | 34.70 | -0.33% |
| HKSE | 25,428.53 | 246.14 | 0.98% |
| NASDAQ | 26,972.62 | 55.15 | 0.20% |
| Nikkei 225 | 66,934.33 | 604.83 | 0.91% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,580.06 | 16.43 | 0.22% |
| S&P/ASX 200 | 8,729.40 | 19.40 | 0.22% |
| SSE Composite Index | 4,057.74 | 10.83 | -0.27% |